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Abstract
Background: Friedreich ataxia (FRDA) is an autosomal recessive neurodegenerative disorder, caused by a GAA repeat
expansion mutation within intron 1 of the FXN gene. We have previously established and performed preliminary
characterisation of several human FXN yeast artificial chromosome (YAC) transgenic FRDA mouse models containing GAA
repeat expansions, Y47R (9 GAA repeats), YG8R (90 and 190 GAA repeats) and YG22R (190 GAA repeats).
Methodology/Principal Findings: We now report extended cellular, molecular and functional characterisation of these FXN
YAC transgenic mouse models. FXN transgene copy number analysis of the FRDA mice demonstrated that the YG22R and
Y47R lines each have a single copy of the FXN transgene while the YG8R line has two copies. Single integration sites of all
transgenes were confirmed by fluorescence in situ hybridisation (FISH) analysis of metaphase and interphase chromosomes.
We identified significant functional deficits, together with a degree of glucose intolerance and insulin hypersensitivity, in
YG8R and YG22R FRDA mice compared to Y47R and wild-type control mice. We also confirmed increased somatic GAA
repeat instability in the cerebellum and brain of YG22R and YG8R mice, together with significantly reduced levels of FXN
mRNA and protein in the brain and liver of YG8R and YG22R compared to Y47R.
Conclusions/Significance: Together these studies provide a detailed characterisation of our GAA repeat expansion-based
YAC transgenic FRDA mouse models that will help investigations of FRDA disease mechanisms and therapy.
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Introduction
Friedreich ataxia (FRDA) is an autosomal recessive neurode-
generative disorder, caused by a GAA repeat expansion mutation
within intron 1 of the FXN gene, resulting in reduced levels of
frataxin protein [1]. Normal individuals have 5 to 40 GAA repeat
sequences, whereas affected individuals have approximately 70 to
more than 1000 GAA triplets [2]. Frataxin is a mitochondrial
protein involved in iron-sulphur cluster and heme biosynthesis [3].
The reduction in frataxin expression leads to oxidative stress,
mitochondrial iron accumulation and consequential cell death,
with the primary sites being neurons of the dorsal root ganglia
(DRG) and the dentate nucleus of the cerebellum [4,5]. FRDA,
which is the most common inherited ataxia, affecting 1:50,000
Caucasians, is characterised by neurodegeneration, cardiomyop-
athy, diabetes mellitus and skeletal deformities [6]. At present
there is no effective treatment for FRDA. To investigate FRDA
molecular disease mechanisms and therapy, we have previously
established three human FXN YAC transgenic mouse models:
Y47R, containing normal-sized (GAA)9 repeats, and YG8R and
YG22R, which initially contained expanded GAA repeats of 90–
190 units and 190 units, respectively, but which have subsequently
been bred to now contain expanded GAA repeats of 120–220
units and 170–260 units, respectively [7]. This was achieved by
crossbreeding human genomic YAC transgenic mice that
contained the entire FXN gene and expanded GAA repeats with
heterozygous Fxn knockout mice [7]. YG8R and YG22R mice are
likely to have impaired function of the human transgene-derived
frataxin leading to functional deficiencies in motor coordination
ability and changes in physical status that are consistent with
FRDA disease. In addition, 10–30% of FRDA patients develop
overt diabetes and 30% have impaired glucose tolerance, which
can result from lack of insulin secretion by the insulin-producing ß
cells in the pancreas, insulin resistance in muscle, liver and fat, or
from a combination of both [8]. Frataxin is involved in iron
metabolism, thus, depletion of frataxin leads to increased levels of
ROS within pancreatic islets, which could lead to both hypergly-
cemia and impaired insulin secretion [9]. Recent studies have
revealed that FRDA patients exhibit some degree of insulin
resistance, suggesting the possibility of an additional role for
frataxin in mediating insulin signalling and insulin secretion [8].
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Previous studies demonstrated that both YG8R and YG22R
FRDA mice expressed comparatively decreased levels of human
frataxin mRNA and protein in comparison to the endogenous
mouse levels [10]. Other studies also revealed YG8R and YG22R
to have decreased mRNA levels in brain and heart tissues
compared to Y47R [11]. Furthermore, YG8R and YG22R mice
exhibited an FRDA-like molecular disease phenotype that
included intergenerational and somatic instability of the GAA
repeat expansion mutation [7,12] as well as progressive functional
deficits compared to wild-type controls that were consistent with
FRDA disease [10]. However, we considered that a more detailed
analysis of the neurological phenotypes of the FXN YAC
transgenic mouse models after several years of breeding, including
investigation of previously untested features such as gait abnor-
mality, was now required. In addition, the behavioural phenotypes
of these mice were previously only compared to a wild-type
control. However, to obtain more comprehensive data, a
transgenic mouse carrying the normal human FXN gene (i.e.
Y47R) may also serve as a useful control model to investigate the
behavioural consequences of reduced FXN in our FRDA mouse
models. In this study we investigate the FXN transgene copy
number in the GAA repeat expansion-based FRDA mice to
determine whether a copy number variation plays a role in disease
or impacts the expression of the FRDA gene. Subsequently, we
demonstrate functional deficits in the YG8R and YG22R
compared to both C57BL6/J (B6) and Y47R controls using
several behavioural assessments. Finally, we correlate frataxin
expression levels and the somatic GAA repeat instability with
FRDA-like pathological phenotype in the FRDA mouse models.
Such studies are crucial to highlight the importance of careful
interpretation of the phenotypes of the mouse models in selecting
the optimum mouse models capable of reproducing features of the
FRDA disease.
Materials and Methods
Transgenic mice, cell culture, DNA extraction and
trinucleotide repeat analysis
Mice were housed in conventional open cages with Litaspen
Premium 8/20 bedding, paper wool nesting and standard fun
tunnel environmental enrichment. The animal husbandry was
carried out at 11 h dark versus 13 h light, 20–23uC and 45–60%
humidity. The mice were nourished with a diet of SDS RM3
expanded food pellets and standard drinking water. All procedures
were carried out in accordance with the UK Home Office
‘Animals (Scientific Procedures) Act 1986’ and with approval from
the Brunel University Animals Welfare and Ethical Review Board.
All mice were maintained in a predominant B6 genetic
background. Mouse fibroblast cell lines were established from
the kidneys of B6 mice and FXN YAC transgenic mouse models as
previously described [7,13,14]. Genomic DNA was extracted from
the FRDA and control mouse tissues and fibroblast cells, by
standard phenol/chloroform extraction and ethanol precipitation.
GAA PCR amplification was carried out with a conventional PCR
kit (Qiagen) using the following primers: GAA-F: 59-
GGGATTGGTTGCCAGTGCTTAAAAGTTAG-39 and GAA-
R: 59-GATCTAAGGACCATCATGGCCACACTTGCC-39.
GAA PCR products were resolved in 20 cm long 1.5% agarose
gels by electrophoresis at 50 V for 16–18 hours and band sizes
were analysed by comparison with 1 kb plus and 100 bp DNA size
markers (Invitrogen). The number of GAA repeats were then
determined by subtracting 451 bp (flanking non-repeat DNA)
from the PCR product size, followed by division of the remaining
base pair repeat size by 3.
Estimation of transgene copy number
TaqMan Copy Number Assays. The frataxin copy number
was determined using TaqMan copy number assays (Applied
Biosystems) according to the manufacturer’s instructions. In brief,
genomic DNA (20 ng) was combined with 26TaqMan universal
master mix, TaqMan copy number assay for human FXN
(Hs05092416_cn or Hs02407730_cn), and TaqMan copy number
reference assay for mouse Tert in a 20 ml reaction volume. The
assay was performed using the 7900-HT real-time polymerase
chain reaction system and the following thermal cycling condi-
tions: 50uC for 2 minutes, 95uC for 10 minutes, and 40 cycles of
95uC for 15 seconds and 60uC for 1 minute. Samples were
assayed using triplicate wells for each gene of interest and copy
numbers were estimated by relative quantitation (RQ) normalised
to the known copy number of the reference sequence using the
comparative Ct (DDCt) method. The Ct data were subsequently
compared to a calibrator sample known to have two copies of the
target sequence, analysed by Applied Biosystems CopyCaller
Software (v.2.0; Applied Biosystems) according to the product
instruction.
Fluorescence in situ Hybridisation Assay. Cell cultures
were harvested after exposure to Colcemid for 4 hours and
chromosome preparations were obtained according to standard
cytogenetic methods. For interphase analysis, samples were
produced with the exception of Colcemid treatment. Cells were
spread onto slides and were then denatured in 70% formamide in
26 SSC at 70uC for 5 minutes. The probes were prepared using
purified DNA from RP11-265B8 and RP11-876N18 BAC clones,
which were labeled by nick translation with biotin and digoxigenin
respectively, according to the manufacturer’s instructions (Roche,
Mannheim, Germany). The labeled DNAs were ethanol precip-
itated together with Cot-1 human DNA (Roche) and resuspended
in 10 ml of hybridisation buffer (Sigma). The probes were
denatured by incubating at 65uC for 10 minutes, followed by
preannealing at 37uC for 10 minutes. Hybridisation was at 37uC
overnight followed by washing with 26 SSC for 5 minutes. The
RP11-265B8 probe was detected with Avidin D-Texas Red,
biotinylated anti-Avidin D and Avidin D-Texas Red (Vector
Laboratories). The RP11-876N18 was detected with mouse anti-
digoxigenin antibody (Sigma-Aldrich) followed by rabbit anti-
mouse-FITC and anti- rabbit-FITC (Sigma-Aldrich). The slides
were mounted in VECTASHIELD (Vector Laboratories, Burlin-
game, CA, USA) containing DAPI counterstain.
Behavioural testing
Body Weight Analysis and Rotarod Test. Mouse body
weights were recorded once a month from 4–12 months of age
using a Mettler Toledo balance (Mettler Toledo PB1501, UK). 10
mice including 5 males and 5 females from each group (B6, Y47R,
YG22R and YG8R) were assessed. The motor deficits associated
with FRDA were assessed using a Ugo-Basille 7650 accelerating
rotarod treadmill apparatus, designated for testing the balance and
coordination aspects of general motor function. Mice were placed
on the rod and four trials were performed with the speed of the
rotation gradually increasing from 4 to 40 rpm. Each trial lasted
approximately 3 to 5 minutes, separated by a rest period of
200 seconds between each trial. The time taken for the mouse to
fall from the apparatus was recorded and the maximum time on
the rotarod was set at 400 s. Mice were assessed monthly for an 8-
month period from 4–12 months of age (i.e. 9 time points).
Beam-breaker Test. Average velocity, ambulatory distance,
vertical counts, vertical time, jump counts and jump time were
measured over a 2 minute period and repeated four times for each
mouse using a beam-breaker activity monitor (MED-OFA-510
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activity chamber, Med Associates). The system consisted of 2
subject containment environment (chamber) and infrared (I/R)
transmitters connected to the computer with data acquisition/
analysis software (SOF-811). Locomotor activity of the mice
(n=10 including 5 males and 5 females used for each group) was
assessed monthly over an 8-month period from 4–12 months of
age. Data analysis and manipulation was performed using
Microsoft Excel.
Beam-walk Test. The beam-walk test was performed to
compare the motor coordination and balance capabilities of
FRDA transgenic and control mice. The test was carried out with
two wooden beams of 90 cm long, one with an external diameter
of 12 mm and the other 22 mm. The beams were placed
horizontally 50 cm above the bench surface with one end
mounted on a narrow support with a 60 W lamp while a darkend
escape box was located at the other end of the beam. Coordination
ability was assessed by measuring the time taken for the mouse to
cross the beam and enter the escape box. Mutant and control mice
received two trainings and were assessed four times on the wider
and narrower beams respectively with a rest period of 5 minutes
between each trial.
Hang Wire Test. The hang wire test was performed to assess
forelimb grip strength. The mice were hung from a horizontally
positioned wire (2 mm in diameter and 30 cm long) with each end
affixed to a vertical stand. Bedding material was placed
underneath the wire to break the fall. The test commenced
shortly after the mouse held onto the wire and the length of time
before the fall was recorded. Four trials were performed with a rest
period of 5 minutes between each trial.
Grip Strength Test. The grip strength meter (Salter
Brecknell Model 12 Spring Balance) was also used to assess the
forelimb grip strength. The mice, held by the base of the tail, were
allowed to freely grasp a metal bar attached to a strain meter. The
peak force with which mice pulled the bar horizontally was
measured in four trials with a rest period of 5 minutes between
each trial.
Footprint Test. To obtain the footprints, mouse paws were
dipped in nontoxic water-based food dye (forepaws in black and
hindpaws in blue colour). The mice were allowed to walk along a
38.5 cm long, 9.5 cm wide gangway (with 7 cm high side walls)
with white paper lining the floor. All mice had one training run
and were then given three trials. Three steps from the middle
portion of each run with a total number of nine steps for each
mouse were measured for left hind and front stride length, right
hind and front stride length, fore base width (the width between
the right and left forelimbs) and hind base width (the width
between the right and left hindlimbs).
Glucose Tolerance Test. To determine fasting blood
glucose levels, 1 mg/g glucose solution (D-Glucose, Sigma
Aldrich) was injected intraperitoneally into the mice after a
16 hour fasting period. Blood glucose was measured from the tail
vein immediately prior to glucose administration and after 20, 40
and 60 minutes with a glucometer (ACCU-CHEK Aviva blood
glucose meter, Roche).
Insulin Tolerance Test. For insulin-tolerance testing, the
mice were fasted for 16 hours. Blood glucose was first measured
from the tail vein, then the mice received an intraperitoneal
injection of insulin (0.75 U/kg, Sigma Aldrich) and blood glucose
was measured again at time points of 20, 50 and 80 minutes after
injection.
Quantitative Reverse Transcriptase PCR
Total RNA was isolated from the mouse tissues by homogeni-
sation with Trizol (Invitrogen) and cDNA was then prepared by
using AMV reverse transcriptase (Invitrogen) with oligo (dT)20
primers following the manufacturer’s instructions. Levels of
human transgenic FXN or endogenous Fxn mRNA expression
were assessed by qPCR using an ABI Prism 7900HT Sequence
Detection System and SYBR Green (Applied Biosystems) with the
following primers that equally amplify human and mouse
sequences: FRT-I forward 59-TTGAAGACCTTGCAGA-
CAAG-39 and RRT-II reverse 59-AGCCA-
GATTTGCTTGTTTGG-39, 121 bp amplicon size. Mouse
Gapdh RT-PCR primers used for normalisation were as follows:
Gapdhm forward 59-ACCCAGAAGACTGTGGATGG-39 and
Gapdhm reverse 59-GGATGCAGGGATGATGTTCT-39, 81 bp
amplicon size. Assays were performed in triplicate in at least two
independent experiments.
Frataxin Dipstick Assay
Protein concentration was quantified by BCA assay and the
levels of frataxin protein were measured by lateral flow immuno-
assay with the Frataxin Protein Quantity Dipstick Assay Kit
(MitoSciences, Eugene, Oregon, USA) according to the manufac-
turer’s instructions [15]. Signal intensity was measured with a
Hamamatsu ICA-1000 Immunochromatographic Reader (MitoS-
ciences).
Statistical analyses
For statistical analysis, unpaired two-tailed Student’s t tests or
two-way analysis of variance (ANOVA) were used to assess the
significance of the differences of the group data with a significance
value set at p,0.05.
Results
Copy number of the FXN transgene
Copy number variation of the FXN transgene was investigated
in YG8R, YG22R, Y47R and wild type (WT) tail biopsy genomic
DNA samples using real-time PCR and unquenching of fluores-
cent probes for the target sequence. The WT line served as a
negative control with no copy number to verify the specificity of
the primers. The results indicated that YG22R and Y47R mice
had a single copy of the FXN transgene whereas the YG8R mice
generally showed two copies of the FXN transgene (Fig. 1a).
However, we also detected an instance where a hemizygous YG8R
mouse had a higher FXN transgene copy number (4 copies),
indicating a degree of potential variation within the YG8R line. In
addition, to determine the integration site of the transgenic FXN
gene and to confirm the TaqMan copy number results,
fluorescence in situ hybridisation (FISH) using dual colour probes
containing overlapping BAC (RP11-265B8 and RP11-876N18)
sequences was performed on both metaphase and interphase
spreads of YG8R, YG22R and Y47R fibroblast cell lines. All three
cell lines were found to have a single integration site by analysis of
metaphase chromosomes (Fig. 1b). YG8R showed three hybrid-
isation signals indicating the presence of a single integration site
containing multiple copies of the FXN transgene whereas YG22R
and Y47R showed one signal indicating one copy of the FXN
transgene (Fig. 1c).
Measurement of Progressive Functional Deficits in FRDA
Mice
Rotarod. Motor coordination was assessed on a rotarod
treadmill at monthly time points from 4–12 months of age in
YG8R and YG22R FRDA mice. B6 and Y47R (containing the
human FXN YAC transgene with normal-sized GAA repeats)
mice were used as the controls. 10 mice were assessed for each
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group, 5 males and 5 females. As shown in Figure 2, the
coordination ability of the YG22R and YG8R mice was
significantly reduced when compared to B6 and Y47R controls.
This trend held true when both male and female values were taken
together (Fig. 2a) or when male and female values were considered
alone (Fig. 2b and c). The body weight was also recorded monthly
from 4–12 months of age. YG22R and YG8R mice demonstrated
a significant increase in weight compared to B6 control when both
male and female values were taken together (Fig. 2d). A similar
trend was also observed when male and female values were
considered alone (Fig. 2e and f). The statistical significance of the
differences was evaluated by two-way ANOVA. The increase in
weight may be attributed to the observed decreased locomotor
activity of the mice. However, unlike B6, Y47R showed a
considerable increase in weight in comparison to all the tested
mice, which in turn may have affected their rotarod performance
(Fig. 2). The increased weight of Y47R mice compared to YG8R
and YG22R mice may also be due in part to higher levels of
frataxin expression in the Y47R control mice.
Beam-breaker Test. Locomotor activity tests were per-
formed over a 2 minute period and repeated four times for each
mouse using a beam-breaker activity monitor. 10 mice (5 males
and 5 females) were assessed monthly for each group over an 8-
month period from 4–12 months of age. Statistical analysis was
performed using the two-way ANOVA method for all the
experimental results. As shown in Fig. 3a–c, YG8R and YG22R
mice exhibited significantly lower average velocity (total distance
covered divided by the total time elapsed) compared to B6 and
Y47R controls. A similar trend was observed when male and
female were taken together (Fig. 3a), or analysed separately
(Fig. 3b and 3c). Ambulatory distances (total distance covered by
the mice within a specific time) of FRDA mice was significantly
less than the controls when male and female were taken together
(Fig. S1a). The same trend held true when males (Fig. S1b) and
females (Fig. S1c) were analysed separately. The vertical count and
vertical time (total events and duration when the mouse stands
with the hind legs) were also measured. As shown in Fig. S2a–f,
significant decreases in the vertical count and vertical time were
Figure 1. Transgene copy number. (a) Two TaqMan copy number assays were applied; Hs05092416-cn assay, represented in black, was designed
to amplify a 106 bp fragment of FXN within intron 3 and Hs02407730-cn assay, represented in grey, was designed to amplify an 80 bp fragment of
FXN within intron 1 and exon 2. Wild type (WT) served as a negative control with no copy number. Error bars = SD. n=2. (b and c) Determination of
the integration site of the transgenic FXN gene by FISH. Biotin-labelled RP11-265B8 and digoxigenin- labelled RP11-876N18 probes were hybridised
onto interphase and metaphase chromosomes (DAPI stained) of YG8R, YG22R and Y47R cells. (b) All three cell lines showed a single integration site of
the FXN transgene by metaphase analysis. (c) YG8R showed three hybridisation signals corresponded to the transgenic FXN, whereas YG22R and Y47R
showed one signal indicating one copy of the FXN transgene. Scale bare = 10 mm.
doi:10.1371/journal.pone.0107416.g001
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detected in the FRDA mice compared to the controls when
analysing males and females together and separately. Subsequent-
ly, the jump count and jump time (total number of jumps and
duration that the mouse jumps) were recorded. As shown in Fig.
S3a–f, significant decreases in jump counts, and to a lesser extent
in jump time, were detected in YG8R FRDA mice compared to
the controls when analysing males and females together and males
separately (Table S1). No such significant differences were
detected for YG8R females or YG22R mice.
Beam-walk Test. Beam-walk performance test was used to
assess the coordination ability of 12 month old YG8R and YG22R
FRDA mice compared with B6 and Y47R controls. 10 mice (5
males and 5 females) were assessed for each group and the average
latency of 4 trials on 22 mm and 12 mm diameter beams was
recorded. As evident in Fig. 4a–c, the FRDA mice took
significantly longer to cross both 22 mm and 12 mm beams
compared to the controls when analysing males and females
together. However, no significant difference was detected in the
beam-walk performance of YG22R on the 12 mm beam
compared to Y47R control. This may be due to the higher body
weights of YG22R and Y47R mice, affecting their balance and
performance on the narrower beam. The same trend was observed
when female values were considered alone (Fig. 4c). Although
both female deficient genotypes took longer than B6 and Y47R to
cross the 22 mm and 12 mm beams, the differences between the
YG22R and the controls did not reach the statistical significance
on the latter beam. The significance of these observations was
confirmed by Student’s t test, which indicated a significant effect of
genotype on the latency between mutant and control mice when
traversing both beams. The analysis of YG8R and YG22R males
also showed a coordination deficit on both 22 mm and 12 mm
beams when compared to B6 controls (Fig. 4b). However, detailed
analysis of the male values on the 12 mm beam indicated no
significant difference in comparison to Y47R due to both Y47R
and YG22R having higher weight than YG8R mice. These results
suggest that although the beam-walk is an effective model to assess
severity of the FRDA-like lack of coordination ability, other factors
such as body weight and age might have an impact on the
experimental results. In order to assess the effect of body weight on
animals’ performance, the beam-walk values were normalised by
the body weight. As shown in Fig. S.4, body weight did not change
the pattern of significance when both males and females were
considered together or females alone. However, the difference
between the FRDA and Y47R male mice was significant when the
values were normalised.
Hang Wire Test. This test involved letting the 12 month old
mice hang by their forepaws from a horizontal wire with each end
affixed to a vertical stand and the length of time the mouse held
onto the wire was recorded. 10 mice were assessed for each group
(5 males and 5 females). As represented in Fig. 4d–f, the YG8R
Figure 2. Rotarod and weight analysis. YG22R and YG8R FRDA mice show a coordination deficit compared to B6 and Y47R controls when (a)
both male and female values were taken together (n= 10 mice per genotype) or (b) male alone (n=5 mice per genotype) or (c) female alone (n=5
mice per genotype). (d) Weight analysis of YG22R and YG8R compared to B6 and Y47R controls when both male and female values were taken
together (n= 10 mice per genotype). The results indicated a significant increase in weight of all FRDA mice in comparison to B6 control. A similar
tendency was seen when (e) male and (f) female values were analysed separately (n=5 mice per genotype). Values represent mean 6 SEM.
doi:10.1371/journal.pone.0107416.g002
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Figure 3. Average velocity of FRDA mice. (a) YG8R and YG22R displayed significantly decreased average velocity compared to B6 and Y47R
controls when both male and female values were taken together (n= 10 mice per genotype). Analysis of (b) males and (c) females separately (n=5
mice per genotype) revealed that both deficient genotypes had decreased average velocity compared to the controls. Values represent mean6 SEM.
doi:10.1371/journal.pone.0107416.g003
Figure 4. Beam-walk and hang-wire analysis. (a–c) Beam-walk. (a) Analysis of YG8R and YG22R compared to B6 and Y47R controls showed a
coordination deficit on both 22 mm and 12 mm beams in all rescue mice (n=10 mice per genotype) when both male and female values were taken
together. However, no significant difference in beam-walk of YG22R on the 12 mm beam was observed in comparison to Y47R control. (b) Beam-walk
analysis of YG8R and YG22R male mice compared to B6 control (n= 5 mice per genotype) revealed that both deficient genotypes required
significantly more time to cross the 22 mm and 12 mm beams, however there was no significant difference between these mice and Y47R control. (c)
Analysis of YG8R female (n=5 mice per genotype) showed that these mice took significantly longer than B6 and Y47R to cross both 22 mm and
12 mm beams. Although YG22R followed a similar performance trend as that of YG8R on the 22 mm and 12 mm beams compared to B6 and Y47R
controls, the difference in beam-walk on 12 mm beam was not significant. (d–f) Hang wire. (d) Analysis of YG8R and YG22R revealed impaired
neuromuscular strength and lack of coordinated motor control compared to B6 and Y47R controls when both male and female values were taken
together (n=10 mice per genotype). Analysis of YG8R and YG22R (e) males and (f) females separately (n= 5 mice per genotype) revealed the same
pattern compared to B6 and Y47R controls. However, there was no significant different between all male mutant and Y47R control mice. Values
represent mean 6 SEM. *P,0.05, **P,0.01 and ***P,0.001. Statistical differences between mutant and B6 control mice are indicated by the top bar
while the bottom bar indicates the differences between mutant and Y47R control mice.
doi:10.1371/journal.pone.0107416.g004
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and YG22R mice fell off the wire quicker when compared to
Y47R and B6 controls, suggesting a reduced overall strength. This
trend held true when male and female values were taken together
(Fig. 4d) or when male and female values were considered
separately (for comparison with B6) (Fig. 4e and 4f). Significant
differences between the performances of mutant and control mice
were confirmed by the Student’s t test. A significant difference was
also seen between female mutant and Y47R control mice (Fig. 4f).
However, no significant difference was observed between male
mutant and Y47R control mice (Fig. 4e). This may be attributed
to the heavier weight of Y47R male mice, preventing them from
clinging to the wire for any extended period of time.
Grip Strength Test. To further assess forelimb grip strength,
a grip strength meter was used to measure the peak force with
which mice pulled a wire. Ten 12 month old mice were assessed
for each group (5 males and 5 females). The results showed a
significant decrease in grip strength of both YG8R and YG22R
mice compared to Y47R and B6 controls. This trend held true
when both male and female values were taken together (Fig. 5a),
or when male and female values were considered alone (Fig. 5b
and 5c). The significance of the difference between the groups was
confirmed by Student’s t test, indicating the significance of the
difference between the performance of mutant and control mice.
Footprint Test. Gait abnormalities were assessed by analys-
ing the footprint pattern of 12 month old mice while they walked
along a narrow gangway. As shown in Fig. S5, the control mice
walked in a relatively straight line with a regular and even
alternating stride, whereas YG8R and YG22R mice progressively
moved from side to side while walking along the gangway,
demonstrating an overall loss of controlled movement. Moreover,
further analysis of the footprints indicated a significant decrease in
stride length of YG8R and YG22R FRDA mice compared to
Y47R and B6 controls (Fig. 6a–c). This trend held true when both
male and female values were taken together (Fig. 6a), or when
female values were considered alone (Fig. 6c). However, there was
no significant difference in stride length of YG8R male mice
compared to B6 male controls. FRDA mice were also analysed for
base width and displayed a significantly shorter base width
compared to the controls (Fig. 6d–f). This trend held true when
both male and female values were analysed together (Fig. 6d), or
when male and female values were considered alone (Fig. 6e and
6f). However, there was no significant difference in base width of
YG8R male mice compared to B6 male control. The significance
of the difference between the groups was confirmed by Student’s t
test. The results highlighted the non-uniformity in step alteration
and lack of coordination in FRDA mouse models, also inherent in
FRDA patients.
Glucose and Insulin Tolerance Tests. To determine
potential abnormalities in glucose handling in FRDA mice, a
fasting glucose tolerance test was performed on 12 month old
FRDA and control mice. 10 mice (5 males and 5 females) were
assessed for each group. As evident in Fig. 7a, blood glucose
concentration was higher in FRDA mouse models compared to
Y47R and B6 controls when both male and female values were
analysed together, suggesting glucose intolerance response in these
mice. However due to large individual variations, the differences
did not reach the statistical significance analysed by Student’s t test
(Fig. 7a). A similar tendency was observed when male values were
considered alone. A significant difference was identified in YG22R
at 40 and 60 minute time points compared to both Y47R and B6
controls (P,0.05) (Fig. 7b). Surprisingly, female mice responded
differently to the glucose tolerance test. The glucose levels showed
no difference between female YG22R and control mice, but
YG8R had a higher glucose concentration after 40 minutes
(Fig. 7c). The basal glucose concentrations of FRDA and control
mice were similar, but female mice displayed a lower basal glucose
level than their male counterparts. This might be due to the lower
body weight of the female mice and thus higher insulin sensitivity
(Fig. S6a). To determine insulin sensitivity in FRDA mice, an
insulin tolerance test was performed in FRDA and control mice
after a 16 h fasting period. 0.75 U/kg insulin was administered
intraperitoneally and blood glucose concentration was measured
prior to insulin administration and after 20, 50 and 80 minutes
using a glucometer. 10 YG8R (5 males and 5 females), 9 YG22R
(5 males and 4 females), 8 B6 (2 males and 6 females) and 10 Y47R
(5 males and 5 females) were assessed. As shown in Fig. 7d, all
mice were able to utilise the administered insulin to lower blood
glucose levels. However, YG22R mice showed lower blood glucose
levels after 50 minutes, indicating a relative increase in insulin
sensitivity with respect to controls, Fig. 7d. Both YG8R and
YG22R male mice exhibited a more rapid glucose lowering after
insulin injection, Fig. 7e, and female YG22R mice had a greater
reduction in blood glucose concentration after 50 minutes,
suggesting insulin hypersensitivity, Fig. 7f. However, YG8R had
smaller changes in blood glucose after insulin injection, which may
be due to their lower body weight, Fig. S6b.
Figure 5. Grip strength analysis. (a) Analysis of YG8R and YG22R mice revealed significantly reduced grip strength compared to B6 and Y47R
controls when both males and females were analysed together (n=10 mice per genotype). Analysis of (b) males and (c) females separately (n= 5
mice per genotype) revealed a significant decrease in grip strength of all mutant mice compared to the controls Values represent mean 6 SEM. **P,
0.01 and ***P,0.001. Statistical differences between mutant and B6 control mice are indicated by the top bar while the bottom barindicates the
differences between mutant and Y47R control mice.
doi:10.1371/journal.pone.0107416.g005
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Somatic GAA Repeat Instability in FRDA Mouse Models
Somatic instability of the GAA repeat was assessed in a variety
of tissues from 12 month old YG8R, YG22R and Y47R mice. As
represented in Fig. 8, YG8R mice exhibited a smear of expanding
GAA repeats, extending upward from 215 to 230 GAA repeats,
particularly in the brain and cerebellum tissues and also to some
extent in the liver, but not in any of the other tissues. Size analysis
of GAA sequences from YG8R lines revealed five bands of GAA
repeat alleles, ranging in size from 125 to 215 repeat units (Fig. 8).
GAA repeat instability was also detected in the YG22R mice.
YG22R exhibited a smear of expanding GAA repeats in the brain,
cerebellum and liver tissues from approximately 250 to 258
repeats, the smear was more pronounced in the cerebellum and
liver tissues. Other tissues showed the same characteristic
appearance of 215 to 250 repeats (Fig. 8). Y47R control line
exhibited normal GAA repeat size of 9 units with no somatic
instability (Fig. 8).
Reduced Frataxin mRNA and Protein Levels in FRDA
Mouse Models
To assess the effect of GAA repeat expansion on FXN
expression in the studied FRDA mouse models, qRT-PCR
measurements were performed using primers designed to detect
both human and mouse frataxin cDNA. Analysis of the YG8R and
YG22R mice (both male and female) compared to Y47R controls
revealed that FXN mRNA levels reduced to 55% (P,0.001) and
77% (P,0.06) in the brain, and 48% (P,0.001) and 47% (P,
0.001) in the liver tissues, respectively (Fig. 9a). However, the
YG8R and YG22R did not show any marked reduction of FXN
mRNA compared to the B6 control. On the other hand, analysis
of the male YG8R and YG22R mice revealed reduced FXN
mRNA levels of 57% (P,0.001) and 70% (P=0.2) in the brain,
and 44% (P,0.05) and 44% (P,0.05) in the liver, respectively
(Fig. 9b). Furthermore, the levels of transgenic FXN mRNA
expression in YG8R and YG22R females were decreased to 53%
(P= 0.1) and 84% (P= 0.4) in the brain, and 52% (P,0.05) and
50% (P,0.05) in the liver tissues, respectively (Fig. 9c). To
determine the levels of human frataxin expression in the FRDA
mouse models, frataxin protein expression levels were measured
by lateral flow immunoassay with the Frataxin Protein Quantity
Dipstick assay kit. Analysis of FRDA males and females together
revealed that the frataxin expression was significantly decreased in
the brain tissues derived from YG8R and YG22R mice to
approximately 76% (P,0.01) and 60% (P,0.001) respectively
compared to Y47R control (Fig. 9d). Significant reduction in the
FXN protein expression was also observed in the liver of YG8R
(65%, P,0.001) and YG22R (51%, P,0.001) compared to Y47R
Figure 6. Footprint analysis. (a–c) Stride length (average of both left and right hindlimb, and left and right forelimb) analysis of mice. (a) Analysis
of YG8R andYG22R mice revealed significantly reduced stride length compared to B6 and Y47R controls when both male and female values were
taken together (n= 10 mice per genotype). Analysis of (b) males and (c) females separately (n= 5 mice per genotype). (d–f) Base width (average of
forelimb and hindlimb base width) analysis of mice. (d) Analysis of YG8R and YG22R mice revealed significantly shorter base width compared to B6
and Y47R controls when both male and female values were taken together (n= 10 mice per genotype). Analysis of (e) males and (f) females
separately (n= 5 mice per genotype) revealed a significant decrease in base width of both mutant mice compared to controls. Values represent mean
6 SEM. *P,0.05, **P,0.01 and ***P,0.001. Statistical differences between mutant and B6 control mice are indicated by the top bar while the bottom
bar indicates the differences between mutant and Y47R control mice.
doi:10.1371/journal.pone.0107416.g006
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control (Fig. 9d). Males and females were also analysed separately
in order to determine the gender-specific differences in the FXN
expression level. The results from the males revealed a significant
decrease of FXN expression in the brain of YG8R (85%, P,0.05)
and YG22R (66%, P,0.01), and also in the liver of YG8R (44%,
P,0.01) and YG22R (45%, P,0.001) (Fig. 9e). Analysis of the
females showed a marked reduction of FXN expression in the
brain of YG8R (50%, P,0.01) and YG22R (48%, P,0.05) female
mice (Fig. 9f). The same trend was also observed in the liver of
YG8R (79%, P,0.001) and YG22R (55%, P,0.001) females
(Fig. 9f). However, since this approach uses a human-specific anti-
frataxin antibody, it did not allow comparison of the human
frataxin levels in the FRDA transgenic mice with B6 mouse
frataxin levels.
Discussion
FRDA is an autosomal recessive neurodegenerative disorder
caused by a reduction in frataxin expression [1]. The reduction in
frataxin expression leads to oxidative stress, mitochondrial iron
accumulation and consequential cell death with the primary sites
of neurons of the dorsal root ganglia and the dentate nucleus of the
cerebellum, contributing to symptoms of progressive ataxia,
muscle weakness, and sensory deficit [16–20]. To recapitulate
such features of FRDA disease in the mouse, we generated
different GAA repeat expansion-based FXN YAC transgenic
mouse models. In this study, we first investigated the difference in
the FXN transgene copy number in YG8R, YG22R and Y47R
lines and we found that the YG22R and Y47R lines had a single
copy of the FRDA transgene while the YG8R line had two copies
of the FRDA transgene. These results were in good agreement
with those previously reported [7,13]. However, it is important to
note that a degree of copy number variation was observed within
hemizygous YG8R DNA samples. Therefore, care must be taken
to determine the copy number of YG8R mice when considering
these mouse models for experimental studies and FRDA
therapeutic approaches. We previously demonstrated that both
YG22R and YG8R FRDA mice expressed comparatively
decreased levels of human frataxin in comparison to the
endogenous mouse levels [10]. Therefore, it was hypothesised
that the 190 and 190+90 GAA repeat expansion mutation sizes
within YG22 and YG8 may induce the FRDA-like pathological
phenotype and functional deficits. To determine the effect of
reduced frataxin level on FRDA-like pathological phenotype and
functional deficits, coordination ability of YG8R and YG22R mice
was assessed using an accelerating rotarod apparatus over an 8-
Figure 7. Glucose and insulin tolerance tests. (a–c) Glucose tolerance test. (a) Glucose concentration was higher in YG8R and YG22R compared
to B6 and Y47R controls when both male and female values were taken together (n=10 mice per genotype). (b) Similar results were obtained when
male values were considered alone (n=5 mice per genotype). (c) Analysis of female mice showed no difference between the FRDA and control mice
(n=5 mice per genotype). (d–f) Insulin tolerance test. (d) YG8R and YG22R showed lower blood glucose level after insulin injection compared to B6
and Y47R controls when both male and female values were considered. (e) Although the blood glucose concentration was normalised after
50 minutes, FRDA male mice exhibited a more rapid glucose lowering after insulin injection. (f) Female mice showed a greater reduction in blood
glucose concentration after 50 minutes. Values represent mean 6 SEM. *P,0.05, **P,0.01 and ***P,0.001.
doi:10.1371/journal.pone.0107416.g007
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month period from 4 to 12 months of age. B6 and Y47R
(containing the human FXN YAC transgene with normal-sized
GAA repeats) were used as the controls. The YG8R and YG22R
showed a significant decline in their motor function compared to
B6 and Y47R controls, though, the degree of impairment was
more significant in YG8R mice. On the other hand, analysis of the
male and female values alone indicated that the former are more
affected than the latter. This may be due to several factors. Firstly,
lower body weight of the females may have contributed to the
improved function of these mice. Secondly, females may be more
capable of adapting to the experimental environment and
conditions compared to the male mice. Moreover, body weight
analysis of YG22R and YG8R demonstrated an increase in weight
compared to B6. The increase in weight may be attributed to the
observed decreased locomotor activity of the mice. However,
unlike B6, Y47R showed a considerable increase in weight in
comparison to all the tested mice. Therefore, it is suggested to use
B6 as the control in future rotarod studies. The coordination
deficiency in YG8R and YG22R was previously assessed by
rotarod analysis and open field assay using WT control [10]. The
results obtained as part of this investigation were in good
agreement with those previously reported [10], further supporting
the notion that the additional 90 GAA repeats in the YG8 line
may be responsible for an even more pronounced functional
deficiency. The locomotor activity analysis using beam-breaker
apparatus showed a significant decrease in average velocity,
ambulatory distance, vertical time, vertical count, jump time and
jump count of the mutant mice compared to B6 and Y47R
controls which were consistent with those previously reported [10].
To further assess the motor behaviour and balance in the FRDA
mice, beam-walk test was utilised using two different beam sizes,
12 mm and 22 mm. The results indicated that the FRDA mice
took significantly longer to cross both beams in comparison to the
controls. However the difference was more significant when
compared to the B6 control. This may be due to the higher body
weight of Y47R mice, affecting their balance and performance.
Muscle strength, assessed by forelimb grip strength and hang wire
tests, was significantly decreased in the FRDA mice compared to
B6 and Y47R controls. Gait parameters (stride length and base
width) of the mutant and control mice were also evaluated by
footprint analysis. The results showed a non-uniform gait pattern
with significantly decreased stride length and base width in the
FRDA mice compared to B6 and Y47R controls. The identified
functional deficits in the FRDA mouse models may be due to the
reduced levels of frataxin, inducing an FRDA-like phenotype. If
so, then these functional tests provide an experimental approach
capable of detecting the phenotypic consequences of the reduced
level of frataxin in the FRDA mice, making them amenable to
novel therapeutic strategies. Upon consideration of the different
functional studies that could be performed, we would recommend
that the beam walk test is perhaps the most valuable test for
assessing coordination ability of these FRDA mice, because it is
simple to perform and gives good reproducibility and statistically
significant results. Hang-wire, grip strength and footprint analyses
also give reproducible and significant results but are more time-
consuming or more difficult to perform, whereas rotarod and
beam-breaker locomotor analyses require special apparatus and
the results can have a higher degree of variability.
Another symptom of FRDA disease is susceptibility to diabetes.
FRDA patients are at risk of getting increased blood sugar levels or
glucose intolerance, with approximately 20% progressing to overt
diabetes as well as neurological problems. Therefore, glucose and
insulin tolerance tests were performed in the FRDA mouse models
to determine the prevalence of abnormalities in glucose handling
and insulin sensitivity. The glucose tolerance results indicated that
the FRDA mice had a degree of glucose intolerance. However,
males and females responded differently, possibly due to the lower
body weight of the females, thus higher insulin sensitivity. Basal
blood glucose level did not change amongst the tested mouse
models. Taken together, these results indicated that insulin
Figure 8. Somatic GAA repeat instability. A representative 1.5% agarose gel shows GAA repeat PCR products from different somatic tissues (Tail
(Ta), Brain (B), Cerebellum (C), Liver (L), Heart (H), Kidney (K), Pancreas (P)) of YG8R (Lanes 2 to 9); YG22R (Lanes 10 to 16) and Y47R (Lanes 17 to 23)
lines. 1 kb+ and 100 bp DNA ladders were used as the molecular marker.
doi:10.1371/journal.pone.0107416.g008
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secretion following a glucose injection may be delayed in the
FRDA mice. This delay was more pronounced in males,
suggesting that increased body weight contributed to insulin
resistance. Furthermore, the glucose-lowering effect of exogenous
insulin was enhanced in the FRDA mouse models during insulin
tolerance testing, suggesting a degree of insulin hypersensitivity
within these lines. Insulin hypersensitivity supports the existence of
several pathways of insulin signalling, promoting glucose uptake
and utilisation in peripheral tissues by either insulin-dependent or
insulin-independent mechanisms. These results were consistent
with those previously reported [8], suggesting mitochondrial
dysfunction due to frataxin deficiency in the FRDA mouse models
may contribute to pancreatic ß cell dysfunction. Therefore, it may
be of interest to assess the relative contribution of insulin resistance
and ß cell dysfunction or deficiency in genes of the insulin receptor
substrate (IRS) family in the future studies. This may provide a
novel treatment strategy for the prevention of the disorder
envisaged in FRDA patients.
To further investigate the correlation between FRDA-like
pathological phenotype and frataxin deficiency in the studied
mouse models, the size of the GAA repeats as well as somatic GAA
instability were examined in tissues of YG8R, YG22R and Y47R
mice. The results revealed GAA repeat somatic instability pattern
in the brain, cerebellum and liver of all the FRDA mouse models.
These results were in good agreement with the previous studies
which also showed somatic GAA repeat instability in the brain and
cerebellum of both YG22 and YG8 transgenic mice [7,12].
However, there were differences in the pattern and size of the
GAA repeats between YG22R and YG8R, which might be related
to the pattern of frataxin expression. Subsequently, frataxin
mRNA and protein levels were investigated. The results indicated
significant and consistent reduction in the levels of frataxin mRNA
and protein in the brain and liver samples of YG8R and YG22R
mice compared to Y47R mice. However, the YG8R and YG22R
mice did not exhibit any marked reduction in the FXN mRNA
level compared to the B6 control mice. This might be partially due
to a base pair difference between the sequence of one of the mouse
and human primers, although the base pair is within the less
critical 59 region of the primer. The second possible cause may be
due to the differences in the functional potential and expression
profiles of the endogenous mouse and human transgenic frataxin
since they may be modulated by different regulatory factors.
Therefore, such differences should be considered when using these
mice for preclinical models of human disease. Another point to
consider is our finding that YG8R mice tend to perform worse in
most of the functional tests compared to YG22R mice, despite
Figure 9. Frataxin expression levels. (a–c) qRT–PCR analysis of transgenic FXN mRNA using mouse-human specific primers. (a) Analysis of males
and females together. Analysis of (b) males and (c) females separately. Data were normalised to the mean FXN mRNA level of Y47R brain samples
taken as 100%. Statistical differences between the mutant and B6 controls are indicated by the top bar while the bottom bar indicates the differences
between the mutant and Y47R controls. (d–f) Dipstick immunoassay of human frataxin protein. (d) Analysis of males and females together, (e) males
and (f) females separately. Data were normalised to the mean FXN level of Y47R samples taken as 100%. Values represent mean 6 SEM. *P,0.05,
**P,0.01 and ***P,0.001. n= 4–8.
doi:10.1371/journal.pone.0107416.g009
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having similar levels of FXN mRNA and slightly higher levels of
frataxin protein in brain and liver tissues. These findings suggest
that perhaps only one of the two YG8R FXN transgenes is
transcribed and also casts some doubt upon the absolute
relationship between the levels of frataxin protein expression in
these tissues and the degree of functional performance by these
FRDA mice. There could be many reasons for this apparent
discrepancy, but too much weight for YG8R mice does not seem
to be an issue, since there is no difference in the weight of YG8R
and YG22R male mice, while YG8R female mice actually weigh
less than the YG22R female mice. We would speculate that the
YG8R mice have a greater degree of variability at the FXN
transgenic locus than the YG22R mice, as evidenced by multiple
copies of GAA repeat sequence. Therefore, although bulk brain
and liver tissues, containing many different cell types, show higher
overall levels of frataxin expression in YG8R mice than YG22R
mice, it is possible that specific cells in important FRDA-relevant
disease regions, such as neurons in the dentate nucleus of the
cerebellum or large sensory neurons of the DRG, may actually
have larger progressive GAA repeat expansion mutations, and
hence lower levels of frataxin, in YG8R mice than in YG22R
mice, which may in part be responsible for reduced functional
performance. Further detailed analysis of frataxin expression levels
in subsets of specific cells, a rather difficult technical challenge,
would be required to confirm our speculation. Another speculation
is that, although YG8R mice show higher levels of frataxin protein
in brain and liver tissues than YG22R mice, for some reason not
all of this protein is fully functional.
Several therapeutic approaches have been tested on FRDA
mouse models to treat the downstream events of frataxin deficit,
such as oxidative stress, mitochondrial iron accumulation, and
more recently to increase the level of frataxin. Interferon gamma
(IFNc), a cytokine involved in multiple aspects of iron metabolism
and the immune response [21,22], has been shown to increase
frataxin levels in both cell and animal models of FRDA [23]. It
was reported that in vivo treatment of YG8R mice with IFNc
enhances both locomotor activity and motor coordination, and
induces the upregulation of cellular frataxin and neuronal
preservation in DRG [23]. In addition, understanding the
mechanisms of GAA repeat expansion-induced histone deacetyla-
tion of the FXN gene has led to the use of HDAC inhibitors as
potent candidates to prevent deacetylation of histones and increase
FXN gene transcription through relaxation of chromatin confor-
mation [24]. These studies are supported by the results from a five-
month study on the YG8R mice which confirmed the positive
effects of HDAC inhibitors by reversing frataxin gene silencing
[25].
Our GAA-repeat based YAC transgenic mouse models of
FRDA display some of the characteristic features observed in
FRDA patients, including reduced frataxin expression levels,
somatic instability of the GAA repeat, progressive phenotype with
coordination impairments, together with locomotor defects, and
some aspects of the diabetes. Therefore, study of YG8R and
YG22R mice may contribute to our further understanding of the
pathophysiology of FRDA disease. Indeed, gene expression
profiling of DRG from the YG8R mouse model has already
provided evidence for the involvement of defective expression of
antioxidants and Nrf2 in FRDA [26]. Since the FRDA YAC
transgenic mice exhibit somatic GAA repeat instability, consistent
with the findings in FRDA patients, they are well suited for further
detailed studies of FRDA GAA-repeat molecular disease mecha-
nisms. In particular, it would be interesting to determine the
potential contribution of age-related and tissue-selective GAA
repeat expansions in the progression of FRDA disease. The GAA-
repeat based YAC transgenic mice also provide a useful resource
for FRDA preclinical therapeutic testing, complementing the other
differently designed FRDA mouse models, such as the conditional
knockout mouse models (containing tissue-specific exon 4 deletions
of the Fxn gene) [27] and KIKO mice (containing a (GAA)230
repeat expansion in the first intron of the mouse Fxn locus) [28].
In particular, our FRDA YAC transgenic mice will be of great
value for testing pharmacological compounds that require human-
specific FXN gene sequence to induce a frataxin-increasing effect,
such as potential RNA-based therapies. However, both the YG8R
and the YG22R mice have rather late-onset, mild phenotypic
effects, together with intergenerational GAA repeat variability.
Therefore, it would be advantageous to develop further GAA
repeat-based FRDA transgenic mice that contain a single-copy
large GAA repeat expansion mutation, which may produce a
more severe earlier-onset phenotype. Such transgenic mice could
be generated from the genetic modification of more stable human
bacterial artificial chromosome (BAC) clones rather than YAC
clones, since FXN BAC transgenic mice have also been shown to
rescue the mouse Fxn knockout embryonic lethality [29].
Supporting Information
Figure S1 Ambulatory distance. (a) YG8R and YG22R
displayed significantly decreased ambulatory distance compared to
B6 and Y47R controls when both male and female values were
taken together (n=10 mice per genotype). Analysis of (b) males
and (c) females separately (n=5 mice per genotype) revealed the
same pattern. Values represent mean 6 SEM.
(TIF)
Figure S2 Vertical time and counts. (a) Vertical time and
(d) counts were significantly decreased in YG8R and YG22R
compared to B6 and Y47R controls when both male and female
values were analysed together (n=10 mice per genotype). Analysis
of (b, e) males and (c, f) females separately (n=5 mice per
genotype) revealed the same pattern. Values represent mean 6
SEM.
(TIF)
Figure S3 Jump time and counts. (a) Jump time and (d)
count were significantly decreased in YG8R and YG22R
compared to B6 and Y47R controls when both male and female
values were taken together (n=10 mice per genotype). Analysis of
(b, e) males and (c, f) females separately (n=5 mice per
genotype) revealed the same pattern. Values represent mean 6
SEM.
(TIF)
Figure S4 Beam-walk analysis corrected for body
weight. (a) Body weight corrected beam-walk analysis of
YG8R and YG22R FRDA mice compared with B6 and Y47R
controls (n=10 mice per genotype) when both male and female
values were taken together. (b) Analysis of male and (c) females
(n=5 mice per genotype). Values represent mean 6 SEM. *P,
0.05, **P,0.01 and ***P,0.001. Statistical differences between
mutant and B6 control mice are indicated by the top bar while the
bottom bar indicates the differences between mutant and Y47R
control mice.
(TIF)
Figure S5 Footprint analysis. Footprint patterns were
quantitatively assessed for six parameters including left hind and
front stride length, right hind and front stride length, fore base
width and hind base width as shown on footprint patterns of a
control (top panel) and FRDA mouse (bottom panel).
(TIF)
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Figure S6 Weight analysis. The disparity in body weight of
males and females used for (a) glucose tolerance and (b) insulin
tolerance tests. Values represent mean 6 SEM. *P,0.05, **P,
0.01 and ***P,0.001 analysed by Student’s t test.
(TIF)
Table S1 Two-way ANOVA analysis of locomotor activ-
ity in FRDA mice.
(DOCX)
Acknowledgments
We thank Joe Sarsero for providing the RP11-265B8 and RP11-876N18
BAC clones used for FISH experiments.
Author Contributions
Conceived and designed the experiments: SAV SA MAP. Performed the
experiments: SAV CS SA MAP. Analyzed the data: SAV SA MAP.
Contributed to the writing of the manuscript: SAV SA MAP.
References
1. Campuzano V, Montermini L, Molto MD, Pianese L, Cossee M, et al. (1996)
Friedreich’s ataxia: Autosomal recessive disease caused by an intronic GAA
triplet repeat expansion. Science 271: 1423–1427. doi: 10.1126/sci-
ence.271.5254.1423
2. Pandolfo M (2002) The molecular basis of Friedreich ataxia. Adv Exp Med Biol
516: 99–118.
3. Gerber J, Muhlenhoff U, Lill R (2003) An interaction between frataxin and
Isu1/Nfs1 that is crucial for Fe/S cluster synthesis on Isu1. EMBO Rep 4: 906–
911.
4. Campuzano V, Montermini L, Lutz Y, Cova L, Hindelang C, et al. (1997)
Frataxin is reduced in Friedreich ataxia patients and is associated with
mitochondrial membranes. Hum Mol Genet 6: 1771–1780. doi: 10.1093/
hmg/6.11.1771
5. Koeppen AH (2011) Friedreich’s ataxia: Pathology, pathogenesis, and molecular
genetics. J Neurol Sci 303: 1–12. doi: 10.1016/j.jns.2011.01.010
6. Pandolfo M (2009) Friedreich ataxia: The clinical picture. J Neurol 256 Suppl 1:
3–8. doi: 10.1007/s00415-009-1002-3
7. Al-Mahdawi S, Pinto RM, Ruddle P, Carroll C, Webster Z, et al. (2004) GAA
repeat instability in Friedreich ataxia YAC transgenic mice. Genomics 84: 301–
310. doi: 10.1016/j.ygeno.2004.04.003
8. Cnop M, Igoillo-Esteve M, Rai M, Begu A, Serroukh Y, et al. (2012) Central
role and mechanisms of beta-cell dysfunction and death in Friedreich ataxia-
associated diabetes. Ann Neurol 72: 971–982. doi: 10.1002/ana.23698
9. Ristow M, Mulder H, Pomplun D, Schulz TJ, Muller-Schmehl K, et al. (2003)
Frataxin deficiency in pancreatic islets causes diabetes due to loss of beta cell
mass. J Clin Invest 112: 527–534.
10. Al-Mahdawi S, Pinto RM, Varshney D, Lawrence L, Lowrie MB, et al. (2006)
GAA repeat expansion mutation mouse models of Friedreich ataxia exhibit
oxidative stress leading to progressive neuronal and cardiac pathology.
Genomics 88: 580–590. doi: 10.1016/j.ygeno.2006.06.015
11. Al-Mahdawi S, Pinto RM, Ismail O, Varshney D, Lymperi S, et al. (2008) The
Friedreich ataxia GAA repeat expansion mutation induces comparable
epigenetic changes in human and transgenic mouse brain and heart tissues.
Hum Mol Genet 17: 735–746. doi: 10.1093/hmg/ddm346
12. Clark RM, De Biase I, Malykhina AP, Al-Mahdawi S, Pook M, et al. (2007) The
GAA triplet-repeat is unstable in the context of the human FXN locus and
displays age-dependent expansions in cerebellum and DRG in a transgenic
mouse model. Hum Genet 120: 633–640. doi: 10.1007/s00439-006-0249-3
13. Pook MA, Al-Mahdawi S, Carroll CJ, Cossee M, Puccio H, et al. (2001) Rescue
of the Friedreich’s ataxia knockout mouse by human YAC transgenesis.
Neurogenetics 3: 185–193.
14. Sandi C, Sandi M, Jassal H, Ezzatizadeh V, Anjomani-Virmouni S, et al. (2014)
Generation and characterisation of friedreich ataxia YG8R mouse fibroblast and
neural stem cell models. PLoS One 9: e89488. doi: 10.1371/journal.
pone.0089488
15. Willis JH, Isaya G, Gakh O, Capaldi RA, Marusich MF. (2008) Lateral-flow
immunoassay for the frataxin protein in Friedreich’s ataxia patients and carriers.
Mol Genet Metab 94: 491–497. doi: 10.1016/j.ymgme.2008.03.019
16. Bradley JL, Blake JC, Chamberlain S, Thomas PK, Cooper JM, et al. (2000)
Clinical, biochemical and molecular genetic correlations in Friedreich’s ataxia.
Hum Mol Genet 9: 275–282. doi: 10.1093/hmg/9.2.275
17. Koeppen AH, Michael SC, Knutson MD, Haile DJ, Qian J, et al. (2007) The
dentate nucleus in Friedreich’s ataxia: The role of iron-responsive proteins. Acta
Neuropathol 114: 163–173. doi: 10.1007/s00401-007-0220-y
18. Foury F, Cazzalini O (1997) Deletion of the yeast homologue of the human gene
associated with Friedreich’s ataxia elicits iron accumulation in mitochondria.
FEBS Lett 411: 373–377. doi: 10.1016/s0014-5793(97)00734-5
19. Wong A, Yang J, Cavadini P, Gellera C, Lonnerdal B, et al. (1999) The
Friedreich’s ataxia mutation confers cellular sensitivity to oxidant stress which is
rescued by chelators of iron and calcium and inhibitors of apoptosis. Hum Mol
Genet 8: 425–430. doi: 10.1093/hmg/8.3.425
20. Waldvogel D, van Gelderen P, Hallett M (1999) Increased iron in the dentate
nucleus of patients with friedrich’s ataxia. Ann Neurol 46: 123–125. doi:
10.1002/1531-8249(199907)46:1,123::aid-ana19.3.0.co;2-h
21. Young HA, Bream JH (2007) IFN-gamma: Recent advances in understanding
regulation of expression, biological functions, and clinical applications. Curr Top
Microbiol Immunol 316: 97–117.
22. Miller CH, Maher SG, Young HA. (2009) Clinical use of interferon-gamma.
Ann N Y Acad Sci 1182: 69–79. doi: 10.1111/j.1749-6632.2009.05069.x
23. Tomassini B, Arcuri G, Fortuni S, Sandi C, Ezzatizadeh V, et al. (2012)
Interferon gamma upregulates frataxin and corrects the functional deficits in a
Friedreich ataxia model. Hum Mol Genet 21: 2855–2861. doi: 10.1093/hmg/
dds110
24. Gottesfeld JM, Pandolfo M (2009) Development of histone deacetylase inhibitors
as therapeutics for neurological disease. Future Neurol 4: 775–784.
25. Sandi C, Pinto RM, Al-Mahdawi S, Ezzatizadeh V, Barnes G, et al. (2011)
Prolonged treatment with pimelic o-aminobenzamide HDAC inhibitors
ameliorates the disease phenotype of a Friedreich ataxia mouse model.
Neurobiol Dis 42: 496–505. doi: 10.1016/j.nbd.2011.02.016
26. Shan Y, Schoenfeld RA, Hayashi G, Napoli E, Akiyama T, et al. (2013) Frataxin
deficiency leads to defects in expression of antioxidants and Nrf2 expression in
dorsal root ganglia of the Friedreich’s ataxia YG8R mouse model. Antioxid
Redox Signal 19: 1481–1493. doi: 10.1089/ars.2012.4537
27. Puccio H, Simon D, Cossee M, Criqui-Filipe P, Tiziano F, et al. (2001) Mouse
models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and
fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nat Genet
27: 181–186.
28. Miranda CJ, Santos MM, Ohshima K, Smith J, Li L, et al. (2002) Frataxin
knockin mouse. FEBS Lett 512: 291–297.
29. Sarsero JP, Li L, Holloway TP, Voullaire L, Gazeas S, et al. (2004) Human
BAC-mediated rescue of the Friedreich ataxia knockout mutation in transgenic
mice. Mamm Genome 15: 370–382.
Characterisation of YAC Transgenic Mouse Models of Friedreich Ataxia
PLOS ONE | www.plosone.org 13 September 2014 | Volume 9 | Issue 9 | e107416
